Outcome after previous treatment in chronic lymphocytic leukemia (CLL).
| Treatment . | No. of Patients . | OR (%) . | CR (%) . | Duration of Response (m) . | Ref . |
|---|---|---|---|---|---|
| * Includes CR rate and duration of response for some previously untreated as well as relapsed patients. | |||||
| Abbreviations: OR, overall response: CR, complete response; CLB chlorambucil, P prednisone, COP cyclophosphamide, vincristine, prednisone, CAP cyclophosphamide, doxorubicin, prednisone. | |||||
| Alkylator-based therapy | |||||
| CLB/P daily | 12 | 33 | 0 | 7* | 1 |
| CLB/P monthly | 9 | 22 | 0 | 16* | 1 |
| CLB/P | 17 | 35 | 0 | 8* | 2 |
| COP | 18 | 28 | 0 | 2 | 2 |
| COP | 24 | 25 | 12 | 18 | 3 |
| COP | 13 | 62 | 31 | NA | 4 |
| CAP | 48 | 27 | 6 | 6 | 5 |
| Fludarabine | |||||
| schedule | |||||
| 20 x 5 | 32 | 13 | 3 | NA | 7 |
| 25 or 30 x 5 | 78 | 59 | 15 | 21 | 8 |
| 30 x 5 (+/− P) | 169 | 52 | 37 | 22 | 9 |
| 30 x 3 | 80 | 46 | 10 | NA | 10 |
| 25 x 5 | 48 | 48 | 13 | 11 | 5 |
| 25 x 5 (+/− P) | 703 | 32 | 3 | 13 | 11 |
| 25 x 5 (+/− P) | 374 | 48 | 23 | NA | 12 |
| 2-Chlorodeoxyadenosine | |||||
| 0.2–0.5 mg/kg/day CI x7 | 18 | 22 | 1 | 4.5 | 13 |
| 0.12 mg/kg/day bolus x 5 | 52 | 58 | 31 | 20 | 14 |
| Deoxycoformycin | |||||
| 4 mg/m2 weekly | 28 | 18 | 4 | 9 | 15 |
| 4 mg/m2 weekly then 2wkly | 26 | 15 | 4 | NA | 16 |
| 4 mg/m2 q 1–2 weekly | 17 | 35 | 0 | 6 | 17 |
| Treatment . | No. of Patients . | OR (%) . | CR (%) . | Duration of Response (m) . | Ref . |
|---|---|---|---|---|---|
| * Includes CR rate and duration of response for some previously untreated as well as relapsed patients. | |||||
| Abbreviations: OR, overall response: CR, complete response; CLB chlorambucil, P prednisone, COP cyclophosphamide, vincristine, prednisone, CAP cyclophosphamide, doxorubicin, prednisone. | |||||
| Alkylator-based therapy | |||||
| CLB/P daily | 12 | 33 | 0 | 7* | 1 |
| CLB/P monthly | 9 | 22 | 0 | 16* | 1 |
| CLB/P | 17 | 35 | 0 | 8* | 2 |
| COP | 18 | 28 | 0 | 2 | 2 |
| COP | 24 | 25 | 12 | 18 | 3 |
| COP | 13 | 62 | 31 | NA | 4 |
| CAP | 48 | 27 | 6 | 6 | 5 |
| Fludarabine | |||||
| schedule | |||||
| 20 x 5 | 32 | 13 | 3 | NA | 7 |
| 25 or 30 x 5 | 78 | 59 | 15 | 21 | 8 |
| 30 x 5 (+/− P) | 169 | 52 | 37 | 22 | 9 |
| 30 x 3 | 80 | 46 | 10 | NA | 10 |
| 25 x 5 | 48 | 48 | 13 | 11 | 5 |
| 25 x 5 (+/− P) | 703 | 32 | 3 | 13 | 11 |
| 25 x 5 (+/− P) | 374 | 48 | 23 | NA | 12 |
| 2-Chlorodeoxyadenosine | |||||
| 0.2–0.5 mg/kg/day CI x7 | 18 | 22 | 1 | 4.5 | 13 |
| 0.12 mg/kg/day bolus x 5 | 52 | 58 | 31 | 20 | 14 |
| Deoxycoformycin | |||||
| 4 mg/m2 weekly | 28 | 18 | 4 | 9 | 15 |
| 4 mg/m2 weekly then 2wkly | 26 | 15 | 4 | NA | 16 |
| 4 mg/m2 q 1–2 weekly | 17 | 35 | 0 | 6 | 17 |